Evidence map›Paper›PMID 27167498›Full record

ArticleScientific reports2016

Integrative analysis of extracellular and intracellular bladder cancer cell line proteome with transcriptome: improving coverage and validity of -omics findings.

Agnieszka Latosinska, Manousos Makridakis, Maria Frantzi, Daniel M Borràs, Bart Janssen, William Mullen, Jerome Zoidakis, Axel S Merseburger, Vera Jankowski, Harald Mischak and 1 more

Abstract read
In one paragraph

Article in Scientific reports, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed.

  1. Article
  2. Article
  3. Moesin (Cancers · 2020
    Article
  4. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors.

Agnieszka LatosinskaBiotechnology Division, Biomedical Research Foundation of the Academy of Athens, Athens, Greece.
Manousos MakridakisBiotechnology Division, Biomedical Research Foundation of the Academy of Athens, Athens, Greece.
Maria FrantziMosaiques Diagnostics GmbH, Hannover, Germany.
Daniel M BorràsGenomeScan B.V., Leiden, The Netherlands.
Bart JanssenGenomeScan B.V., Leiden, The Netherlands.
William MullenBHF Glasgow Cardiovascular Research Centre, University of Glasgow, Glasgow, United Kingdom.
Jerome ZoidakisBiotechnology Division, Biomedical Research Foundation of the Academy of Athens, Athens, Greece.
Axel S MerseburgerDepartment of Urology, University of Lübeck, Lübeck, Germany.
Vera JankowskiRWTH-Aachen, Institute for Molecular Cardiovascular Research (IMCAR), Aachen, Germany.
Harald MischakMosaiques Diagnostics GmbH, Hannover, Germany.
Antonia VlahouBiotechnology Division, Biomedical Research Foundation of the Academy of Athens, Athens, Greece.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Characterization of disease-associated proteins improves our understanding of disease pathophysiology. Obtaining a comprehensive coverage of the proteome is challenging, mainly due to limited statistical power and an inability to verify hundreds of putative biomarkers. In an effort to address these issues, we investigated the value of parallel analysis of compartment-specific proteomes with an assessment of findings by cross-strategy and cross-omics (proteomics-transcriptomics) agreement. The validity of the individual datasets and of a "verified" dataset based on cross-strategy/omics agreement was defined following their comparison with published literature. The proteomic analysis of the cell extract, Endoplasmic Reticulum/Golgi apparatus and conditioned medium of T24 vs. its metastatic subclone T24M bladder cancer cells allowed the identification of 253, 217 and 256 significant changes, respectively. Integration of these findings with transcriptomics resulted in 253 "verified" proteins based on the agreement of at least 2 strategies. This approach revealed findings of higher validity, as supported by a higher level of agreement in the literature data than those of individual datasets. As an example, the coverage and shortlisting of targets in the IL-8 signalling pathway are discussed. Collectively, an integrative analysis appears a safer way to evaluate -omics datasets and ultimately generate models from valid observations.

Indexed as

Cell Line, TumorExtracellular SpaceHumansInterleukin-8Intracellular SpaceNeoplasm ProteinsPeptidesProteomeProteomicsReproducibility of ResultsRNA, MessengerSequence Analysis, RNASignal TransductionTranscriptomeUrinary Bladder NeoplasmsInterleukin-8Neoplasm ProteinsPeptidesProteomeRNA, Messenger

Identifiers

PMID27167498
PMCPMC4863247

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.